Moderna Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Updates
(Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today reported financial results and provided business updates for the first quarter 2021 and highlighted pipeline progress.\n\xe2\x80\x9cIn the first quarter, the Moderna team delivered on its supply commitments to many governments and helped protect more than 100 million people.
- (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today reported financial results and provided business updates for the first quarter 2021 and highlighted pipeline progress.\n\xe2\x80\x9cIn the first quarter, the Moderna team delivered on its supply commitments to many governments and helped protect more than 100 million people.
- The Moderna team and our manufacturing partners are working hard to get as close to 1 billion doses in 2021 as we can.
- As detected by three distinct serologic assays, antibodies elicited by the Moderna COVID-19 Vaccine persisted through 6 months after the second dose.
- Moderna owns worldwide commercial rights to mRNA-6981.\nRelaxin (AZD7970): Moderna has regained all rights to the Relaxin development candidate from AstraZeneca.